Every year since 2007, The Scientist Magazine gets hundreds (thousands?) of nominations for their Top 10 Innovations Award.
Pre-arrayed gene families of expression-ready ORFs
Extra measures to ensure we provide you with a viable glycerol stock of your clone!
Now SMARTCas9 gives you a CHOICE of promoters for optimal Cas9 expression in your specific cells.
Ordering guidelines for quantities of crRNA and tracrRNA
The clinical success rate of new oncology drugs is only 3.4% compared to 20.9% in other disease types (Wong et al, 2018). One contributing factor to this issue is the testing systems used, with two-dimensional (2D) monolayer assay formats as the traditional mainstay of high throughput screening. Although 2D monolayer assays have identified many successful drugs, it is increasingly recognized that they do not accurately model key aspects of the three-dimensional (3D) tumor environment. Therefore, the adoption of high throughput screening approaches using 3D assays to complement 2D approaches could substantially improve prediction of clinical outcomes and reduce the high failure rate of cancer drugs in clinical trials.
See the RNAi pathway, timeline and take the quiz!
Learn how reference standards play a key role in increasing and confirming the accuracy of diagnostic testing, thus bringing us closer to precision medicine and targeted therapy.
HAP1 cell lines are a popular choice to validate a range of research experiments, but if you've never used them before, you want to be sure they are right for you.
Liquid biopsy is fast becoming a realistic clinical diagnostic tool, capable of profiling the molecular makeup of a tumor that aids in choosing the right drug and in monitoring treatment response. Studies for its use in early cancer detection are already underway with promising results.